Female Sexual Dysfunction: A Case Study of Disease Mongering and Activist Resistance
Author Information
Author(s): Leonore Tiefer
Primary Institution: New York University School of Medicine
Hypothesis
The creation and promotion of female sexual dysfunction (FSD) exemplifies disease mongering by the pharmaceutical industry.
Conclusion
The medicalization of women's sexual problems has been driven by the pharmaceutical industry, leading to a widespread perception of sexual inadequacy.
Supporting Evidence
- The pharmaceutical industry has aggressively marketed drugs for female sexual dysfunction.
- Activist groups have emerged to challenge the medicalization of women's sexual problems.
- Historical context shows a shift in societal attitudes towards women's sexuality over the 20th century.
Takeaway
This study shows how companies try to convince women they have a problem with their sex life, even when they might not, and how some people are fighting back against this idea.
Methodology
The essay examines historical and cultural factors contributing to the medicalization of female sexual dysfunction.
Potential Biases
Potential bias from pharmaceutical industry influence on research and media representation.
Limitations
The study primarily focuses on the historical context and does not provide new empirical data.
Participant Demographics
Women with female sexual arousal disorder, with a sample size of about 3000.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website